Located in Thousand Oaks, Calif., on May 16, 2025, Amgen (NASDAQ:AMGN) is scheduled to present at the RBC Capital Markets Global Healthcare Conference 2025 on Wednesday, May 21, 2025, at 9:00 a.m. ET. Kave Niksefat, who holds the position of senior vice president of Global Marketing and Access at Amgen, will be the presenter at the event. A live webcast of the presentation will be available online for news media, investors, and the general public.
The webcast, along with other presentations by Amgen’s management at investor and medical conferences concerning the company’s business developments, can be accessed under the Investors section of Amgen’s website,. Details about presentation schedules, webcast accessibility, and links will be provided on Amgen’s Investor Relations Events Calendar. An archived replay of the webcast will be available for a minimum of 90 days following the live event.
About Amgen
Amgen is dedicated to discovering, developing, manufacturing, and delivering groundbreaking medicines that assist millions of patients in their fight against some of the world’s most challenging diseases. Having helped establish the biotechnology industry over 40 years ago, Amgen remains at the forefront of innovation, utilizing technology and human genetic data to explore beyond current boundaries. Amgen is committed to a broad and robust pipeline, expanding upon its existing range of medicines for treating cancer, heart disease, osteoporosis, inflammatory diseases, and rare diseases.
In 2024, Amgen received accolades as one of the “World’s Most Innovative Companies” by Fast Company and was recognized by Forbes as one of “America’s Best Large Employers,” among other honors. Amgen is a component of the Dow Jones Industrial Average®, comprising 30 companies, and is also included in the Nasdaq-100 Index®, which features the largest and most innovative non-financial entities listed on the Nasdaq Stock Market, based on their market capitalization.
For additional details, please visit and connect with us on (formerly Twitter), , , , and .
CONTACT: Amgen, Thousand Oaks
Elissa Snook, 609-251-1407 (media)
Justin Claeys, 805-313-9775 (investors)
SOURCE Amgen
“`